Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

For Industry

Agenda, PDUFA Public Meeting February 16, 2007

8:00-8:45 am Registration

9:00 am Welcome  
Mark Barnett, M.P.H., FDA Moderator

9:05 am Opening Remarks
Andrew C. von Eschenbach, M.D.
U.S. Food and Drug Administration Commissioner

9:15-9:30 am  Funding Human Drug Review: Resources for Drugs and Biologics
Janet Woodcock, M.D., Chief Medical Officer, FDA

9:30-9:45 am Background and History of PDUFA Program
Steven Galson, M.D., M.P.H., Director, FDA CDER

9:45-10:30 am

FDA Proposed Recommendations for PDUFA IV

Sound Financial Footing 
Theresa Mullin, Ph.D., Assistant Commissioner for Planning
Pre-market Review 

John K. Jenkins, M.D., Director, Office of New Drugs, FDA CDER
Information Management

Malcolm Bertoni, M.S., Director, Planning Staff, FDA Office of Planning


10:30-10:45 amBreak (15 minutes)    

10:45-11:30 amPost-market Safety
Deborah Henderson, Director, Office of Executive Programs, FDA CDER
Advisory Review of Direct-to-Consumer Television Advertising
Jane Axelrad, J.D., Associate Director for Policy, FDA CDER

11:30-12:30 pm Lunch

12:30-4:00 pm 

Public Comment on FDA Proposed Recommendations for PDUFA IV

Patient Perspectives
Consumer Perspectives
Health Professional Perspectives
Industry Perspectives
Other Perspectives


4:00-4:15 pmBreak

4:15-5:00 pmGeneral Public Comments

5:00 pm  Closing Comments
Theresa Mullin, Ph.D., Assistant Commissioner for Planning


Page Last Updated: 06/23/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English